// Biotech and Pharma Therapeutics
From dementia to heart disease: could weight-loss jabs transform chronic conditions? – podcast
September 17, 2024 / Weight-loss / Chronic Disease Treatment / Diabetes / Weight Loss /
Weight-loss drugs like Ozempic and Wegovy, originally developed for diabetes, are showing promise in treating chronic conditions like dementia and heart disease. Scientists are investigating whether these effects go beyond just weight loss.
Sanofi readies to meet US demand for RSV antibody
September 15, 2024 / RSV / AstraZeneca / Sanofi / FDA Approval
Sanofi is prepared to meet U.S. demand for its RSV antibody, Beyfortus, following FDA clearance of a new manufacturing line. The drug prevents RSV in newborns and high-risk children, addressing shortages seen in last year’s RSV season.
Shifting Focus from Medication Costs to Medication Value
September 15, 2024 / Healthcare Cost Reduction / Prescription Drug Use
Shifting focus from medication costs to value emphasizes optimizing drug use through pharmacist-physician collaboration. By leveraging pharmacists’ expertise, medication-related problems decrease, adherence improves, and overall healthcare costs may reduce while enhancing patient outcomes.
SoundHealth Launches First-Ever Real-Time Personalized Allergy Forecast
September 17, 2024 / AI / Allergy Treatment / Allergy Forecast / Acoustic Resonance Therapy
SoundHealth has launched SONUCast, the first AI-powered wearable device providing real-time, personalized allergy forecasts and non-pharmaceutical treatment for allergic rhinitis symptoms. The FDA-approved device uses Acoustic Resonance Therapy (ART) to offer relief without corticosteroids’ side effects.
Roche sets out obesity strategy with manufacturing focus
September 17, 2024 / Novo Nordisk / Eli Lilly / Obesity / Roche
Roche is expanding its obesity treatment strategy, acquiring Carmot Therapeutics for $2.7 billion. The acquisition includes injectable CT-388 and oral CT-996, positioning Roche to compete in the growing obesity market led by Novo Nordisk and Eli Lilly.
// 4th Industrial Revolution
Hackensack Meridian Health Launches 24/7 AI-Powered Primary Care Access
September 16, 2024 / AI-Powered Primary Care / Virtual Healthcare Integration / Hackensack Meridian Health / Partnership
Hackensack Meridian Health is launching HMH 24/7, an AI-powered platform offering seamless integration of virtual and in-person primary care. Developed with K Health, it enhances personalized care and improves efficiency through automated processes and comprehensive patient health data.
Not Your Average Bra: How Bloomer Tech’s Wearable Is Addressing Heart Disease in Women
September 16, 2024 / Wearable Tech / Women’s Heart Health / Cardiovascular Device / Heart Disease Prevention
Bloomer Tech developed a wearable ECG bra to enhance heart disease prevention and treatment for women. Designed to collect comprehensive cardiovascular data, the device aims to improve diagnosis and outcomes, especially for women at risk of heart disease.
Generative AI Shows Promise in Reducing Bias in Opioid Prescriptions
September 16, 2024 / AI / Healthcare / Opioid Prescriptions / Pain Management
A Mass General Brigham study found that generative AI models like ChatGPT-4 and Google’s Gemini show no racial or gender bias in opioid treatment recommendations, highlighting AI’s potential to reduce healthcare disparities in pain management.
AI Agents in Healthcare: Retaining Talent, Improving Patient Care
September 16, 2024 / AI / Healthcare Administration / Healthcare Burnout
AI agents offer scalable, efficient solutions to healthcare’s rising administrative demands. By reducing errors, handling repetitive tasks, and improving workflow precision, AI can alleviate workforce shortages, enhance revenue cycle management, and allow staff to focus on patient care.
Where is Pediatric Innovation Making an Impact?
September 16, 2024 / Mental Health / ADHD and ASD Treatment / Peadiatric Healthcare / Digital Health Solutions
Pediatric innovation, especially in mental health, is advancing through accelerators like KidsX and CTIP. Key focus areas include improving access to care for conditions like ADHD and ASD. Challenges remain in adoption, reimbursement, and scaling digital solutions.
// Business & Markets
New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds
September 16, 2024 / FDA Approval / Eli Lilly / Eczema Therapy / Dermatitis Treatment
Eli Lilly’s newly FDA-approved eczema drug, Ebglyss (lebrikizumab), offers a less frequent dosing schedule compared to competitors like Dupixent and Adbry. It targets IL-13 to reduce inflammation in moderate-to-severe atopic dermatitis, providing new relief options for patients.
New gene therapy company emerges with $26 million
September 16, 2024 / San Diego Biotech / Vironexis Biotherapeutics / Gene Therapy / T-Cell Immunotherapies / Cancer Treatment Innovations
Vironexis Biotherapeutics, a San Diego-based company developing AAV-delivered T-cell immunotherapies for cancer, has emerged with $26 million in seed funding. Its TransJoin AAV gene therapy platform aims to advance novel cancer treatments.
Blue Cross and Blue Shield of Minnesota, Herself Health Shift To VBC Contract
September 15, 2024 / Blue Cross Blue Shield Minnesota / Preventive Care / Women’s Health / Chronic Condition Management
Blue Cross and Blue Shield of Minnesota and Herself Health have transitioned to a value-based care model, prioritizing patient outcomes for women over 65. The new agreement emphasizes preventive care, chronic condition management, and overall healthcare quality improvement.
Health tech company mPulse acquires Zipari
September 17, 2024 / mPulse / Zipari / Healthcare Consumer Engagement / Predictive Analytics
mPulse has acquired Zipari to integrate its Health Experience and Insights (HXI) technology with Zipari’s customer engagement platform. This merger aims to enhance consumer experiences, streamline healthcare workflows, and improve health outcomes for health plans and organizations.
Talkspace to be added to Amazon Health Services
September 17, 2024 / Talkspace Amazon Partnership / Teletherapy Enrollment / Mental Health Services / Online Therapy Access
Talkspace has partnered with Amazon Health Services, allowing Amazon customers to check their insurance coverage and enroll in Talkspace’s mental health services. This collaboration simplifies access to therapy, offering quick pairing with licensed therapists via online sessions.
// Legal & Regulatory
FDA drafts guidance on multiregional clinical trials in oncology
September 16, 2024 / FDA / Oncology / Clinical Trials / US Patient Applicability / Cancer Drug Approval
The FDA’s draft guidance for multiregional oncology clinical trials emphasizes ensuring trial data is applicable to U.S. patients and medical practices. Sponsors are encouraged to consider U.S. representation and patient factors like genetics, disease prevalence, and healthcare access when designing trials.
US FDA approves Eli Lilly’s drug for eczema
September 17, 2024 / Eli Lilly Ebglyss Approval / Drug Approval / FDA
The FDA has approved Eli Lilly’s injectable eczema drug, Ebglyss, for patients aged 12 and older. Ebglyss, which targets the IL-13 protein, offers once-monthly dosing for moderate-to-severe eczema, competing with treatments like Dupixent, Rinvoq, and Cibinqo.
Sandoz, Liquidia score $137M win against United in yearslong generic Remodulin dispute
September 16, 2024 / Sandoz United Therapeutics / Lawsuit / Generic Remodulin Dispute / Pulmonary Arterial Hypertension Drug / Drug Approval
Sandoz won $137 million in damages from United Therapeutics in a dispute over a generic version of Remodulin, a pulmonary arterial hypertension drug. The court ruled that United’s actions breached a 2015 agreement, delaying Sandoz’s product launch.
Withings Sleep Rx Mat receives FDA 510(k) clearance
September 16, 2024 / Sleep Apdnea / FDA / Home Sleep Monitoringt
Withings received FDA 510(k) clearance for its Sleep Rx Mat, a noninvasive, contactless device for diagnosing sleep apnea at home. The mat tracks respiratory rate, heart rate, and sleep disturbances, enabling more precise and continuous monitoring of sleep apnea.
Apple receives FDA clearance for sleep apnea and hearing aid technology
September 16, 2024 / Apple FDA Clearance / AirPods Pro Hearing Aids / Over-the-counter Hearing Tech / Sleep Apnea Detection Algoithm
Apple received FDA clearance for the sleep apnea feature in its Watch Series 10, which analyzes sleep data for apnea risk, and for over-the-counter hearing aid technology embedded in AirPods Pro, using machine learning to adjust sound to users’ hearing needs.
// Research & Development
TIGIT drug from iTeos shrinks lung tumors in trial
September 14, 2024 / Lung Cancer / iTeos / Lung Tumor Immunotherapy
iTeos’ TIGIT-targeting drug, belrestotug, in combination with GSK’s Jemperli, showed promising tumor shrinkage in lung cancer patients during a trial. Response rates were up to 77%, though safety concerns arose due to immune-related deaths. Further studies are ongoing.
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
September 16, 2024 / Pfizer / Braftovi / Lung Cancer / Mutation Testing / Non-small Cell Lung Cancer Treatment
Pfizer is promoting BRAF mutation testing in lung cancer to increase the use of its drug Braftovi, which, in combination with Mektovi, has shown promising Phase 2 results. Pfizer aims for broader adoption, targeting up to 60% of eligible lung cancer patients.
Ten-year survival data show long-term benefit of immunotherapy in melanoma
September 15, 2024 / Opdivo Yervoy Melanoma Trial / Immunotherapy Long-term survival / Bristol Myers Squibb
Ten-year follow-up data from the CHECKMATE-067 trial show that combining Bristol Myers Squibb’s immunotherapies, Opdivo and Yervoy, significantly improves long-term survival for advanced melanoma patients. Median survival reached six years, compared to six to nine months before immunotherapy.
Laughter may be as effective as drops for dry eyes
September 12, 2024 / Laughter Therapy Dry Eyes / Non-invasive Tear Breakup Time
A study published in The BMJ found that laughter therapy was as effective as eye drops in improving dry eye disease symptoms. The trial showed improvements in tear breakup time, meibomian gland function, and mental health without adverse events.
Obesity Pill Races Heats Up as Novo, Roche and Terns Share Data
September 17, 2024 / Oral Obesity Drug Trials / Novo Nordisk / Roche / Weight Loss / Terns Pharmaceuticals
Early-stage data from Novo Nordisk, Roche, and Terns Pharmaceuticals show promising weight loss results for their oral obesity drugs. Roche leads in efficacy but faces tolerability issues, while Terns’ unique approach has caught attention despite concerns over dosing complexity.
// Politics
Biosecure passes House but Senate fate uncertain
September 16, 2024 / Biosecure Act / WuXi AppTec Partnership / Drug Supply Cjhain / Biosecure Bill Impact
The Biosecure Act, passed by the U.S. House, could force U.S. biopharmaceutical companies to sever ties with key Chinese contractors like WuXi AppTec, impacting drug development and supply chains. Biotech companies are preparing for potential disruptions despite uncertainty about Senate approval.
Vance’s confusing health insurance remarks give Democrats a new attack line
September 17, 2024 / JD Vance / Health Insurance / Trump Healthcare Plan / Affordable Care Act Debate
JD Vance’s comments about deregulating health insurance, including using risk pools instead of broad coverage for pre-existing conditions, have provided Democrats with an opportunity to portray the Trump-Vance ticket as opposing popular health insurance protections like the Affordable Care Act.
Bernie Sanders keeps the heat on Novo’s high prices
September 18, 2024 / Bernie Sanders / Novo Nordisk / Drug Prices / Organon Dermavant Acquisition / Vtama Psoriasis Treatment / Applied Therapeutics
Bernie Sanders continues to criticize Novo Nordisk for high drug prices, while Organon acquires Dermavant for $175 million, potentially paying more based on VTama’s success. Applied Therapeutics awaits an FDA decision on govorestat for galactosemia treatment.
US legislation targeting China could hurt California biotech firm with Chinese ties
September 12, 2024 / Biosecure Act / Complete Genomics China Ties / US National Security Biotech / California Biotech
The U.S. House passed the Biosecure Act, citing national security concerns, which could impact California-based Complete Genomics and other companies with Chinese ties by preventing federal funds from reaching them.
Congress targets Chinese influence in health tech. It could come with tradeoffs
September 12, 2024 / Biosecure Act / US Genetic Data Protection / Medical Supply Chain Security
The U.S. House passed the BIOSECURE Act, targeting Chinese-linked companies like California-based Complete Genomics, citing national security concerns. While supporters argue it protects genetic data and reduces reliance on China, opponents warn it could hinder drug development and innovation.